1379615-58-3

Basic information

• Product Name: 1H-PYRAZOLE, 1-[(4-FLUOROPHENYL)METHYL]-4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-
• Synonyms: 1H-PYRAZOLE, 1-[(4-FLUOROPHENYL)METHYL]-4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-;1-(4-fluorobenzyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
• CAS NO: 1379615-58-3
• Molecular Weight: 302.156
• Mol File: 1379615-58-3.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: 1H-PYRAZOLE, 1-[(4-FLUOROPHENYL)METHYL]-4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-PYRAZOLE, 1-[(4-FLUOROPHENYL)METHYL]-4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-(1379615-58-3)
• EPA Substance Registry System: 1H-PYRAZOLE, 1-[(4-FLUOROPHENYL)METHYL]-4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-(1379615-58-3)

Safety Data

• Hazardous Substances Data: 1379615-58-3(Hazardous Substances Data)

Usage

Structure

Contains a pyrazole ring and a fluorophenylmethyl group

Type

Boronic acid derivative

Potential applications

Organic synthesis and pharmaceutical research

Unique features

Boron-containing functionality that may be used as a building block for the synthesis of complex organic molecules

Extent of study

Not well-documented, has not been extensively studied

Upstream product

• 269410-08-4 pyrazole-4-boronic acid pinacol ester 
• 459-46-1 4-Fluorobenzyl bromide 
• 73183-34-3 bis(pinacol)diborane 
• 17201-43-3 4-cyanobenzyl bromide 
• 251925-14-1 4-bromo-1-(4-fluorobenzyl)-1H-pyrazole 

Downstream Products

• 1450642-43-9 3-(1-(4-fluorobenzyl)-1H-pyrazol-4-yl)-5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine 
• 1450642-97-3 C₂₈H₂₃FN₆O₂S 
• 1450642-75-7 5-bromo-3-(1-(4-fluorobenzyl)-1H-pyrazol-4-yl)-1-tosyl-1H-pyrrolo[2,3-b]pyridine 
• 1379615-62-9 4-chloro-2‐(1‐(4-fluorobenzyl)-1H‐pyrazol‐4-yl)quinoline 
• 1379615-36-7 2-(1‐(4‐fluorobenzyl)-1H-pyrazol‐4‐yl)quinolin‐4(1H)‐one 

Relevant articles and documents

Development of Inhibitors of SAICAR Synthetase (PurC) from Mycobacterium abscessus Using a Fragment-Based Approach

Mycobacterium abscessus (Mab) has emerged as a challenging threat to individuals with cystic fibrosis. Infections caused by this pathogen are often impossible to treat due to the intrinsic antibiotic resistance leading to lung malfunction and eventually death. Therefore, there is an urgent need to develop new drugs against novel targets in Mab to overcome drug resistance and subsequent treatment failure. In this study, SAICAR synthetase (PurC) from Mab was identified as a promising target for novel antibiotics. An in-house fragment library screen and a high-throughput X-ray crystallographic screen of diverse fragment libraries were explored to provide crucial starting points for fragment elaboration. A series of compounds developed from fragment growing and merging strategies, guided by crystallographic information and careful hit-to-lead optimization, have achieved potent nanomolar binding affinity against the enzyme. Some compounds also show a promising inhibitory effect against Mab and Mtb. This work utilizes a fragment-based design and demonstrates for the first time the potential to develop inhibitors against PurC from Mab.

Heteroaromatic compound and application thereof to drug

The invention discloses a heteroaromatic compound and application thereof to drug. In particular, the invention provides a heteroaromatic compound or stereoisomers thereof, geometric isomers, tautomers, racemates, nitrogen oxides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof, and a pharmaceutical composition comprising the compound provided by the invention. The invention also discloses application of the compound provided by the invention or the pharmaceutical composition thereofto preparation of a medicine for reatment of autoimmune diseases or proliferative diseases.

Heterocyclic compound

本發明提供一種具有CDK8/19抑制活性之雜環化合物。本發明提供一種如下式代表之化合物(其中各代號均如本文之定義)或其鹽。 The present invention provides a heterocyclic compound possessing CDK8/19 inhibitory activity. The present invention provides a compound represented by the formula wherein each symbol is as defined herein, or a salt thereof.